Search results for " guidelines"

showing 10 items of 472 documents

Registration of childhood cancer: Moving towards pan-European coverage?

2015

Cancer is relatively rare in childhood, but it contributes considerably to childhood mortality, years of life lost per person and late effects in survivors. Large populations need to be covered to set up meaningful studies of these rare conditions. Cancer registries ensure cancer surveillance, thus providing the basis for research as well as policy decisions. In this paper we examine coverage of childhood population by cancer registries in Europe and encourage national cancer registration. Over 200 cancer registries in various stages of development were identified as collecting data on childhood cancer patients in Europe. They cover 52% of the childhood population in the World Health Organi…

Cancer ResearchPediatricsmedicine.medical_specialtyAdolescentChildhood cancerPopulation610 Medicine & healthWorld Health OrganizationNeoplasmsEnvironmental healthHumansMedicinemedia_common.cataloged_instance1306 Cancer ResearchEuropean UnionRegistriesAge of OnsetEuropean unionChildeducationmedia_commoneducation.field_of_studyData collectionbusiness.industryIncidence (epidemiology)Infant NewbornInfantCancer10060 Epidemiology Biostatistics and Prevention Institute (EBPI)medicine.diseaseEuropeYears of potential life lostOncologyChild PreschoolData qualityPractice Guidelines as Topic2730 OncologybusinessEuropean Journal of Cancer
researchProduct

Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment†

2020

### Highlights There is no clear definition of orphan symptoms. There is a group of symptoms that are seldom evaluated in most symptom assessment tools which can be considered as orphan symptoms.1 These are generally prevalent symptoms that are unaddressed in clinical practice, yet often not reported by the patients or by healthcare professionals.2 Orphan symptoms may be defined as symptoms not regularly assessed in clinical practice, and consequently little studied and not properly treated. No epidemiological or clinical studies generally exist to gauge the prevalence of the symptoms chosen; nevertheless, these symptoms are distressing for patients and their families. Orphan symptoms remai…

Cancer ResearchPediatricsmedicine.medical_specialtydiagnosisoncological therapiesMEDLINElcsh:RC254-282Quality of lifeEpidemiologymedicine1506Restless legs syndromeOriginal Researchtreatmentbusiness.industryEvidence-based medicineorphan symptomsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRectal tenesmusclinical practice guidelines; diagnosis; oncological therapies; orphan symptoms; treatmentOncologymedicine.symptombusinessMyoclonusclinical practice guidelinesMuscle crampESMO Open
researchProduct

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.

2014

Contains fulltext : 137861.pdf (Publisher’s version ) (Closed access) BACKGROUND: Care for patients with colon and rectal cancer has improved in the last 20years; however considerable variation still exists in cancer management and outcome between European countries. Large variation is also apparent between national guidelines and patterns of cancer care in Europe. Therefore, EURECCA, which is the acronym of European Registration of Cancer Care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012, the first multidisciplinary consensus conference about…

Cancer ResearchQuality Assurance Health CareColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Delphi methodSurgical oncologyFAMILIAL ADENOMATOUS POLYPOSISTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]MedicineSHORT-COURSE RADIOTHERAPYRectal cancerQuality assurance; Colon cancer; Rectal cancer; Multidisciplinary teams; Consensus; Delphi method; Audit; Neoadjuvant treatment; Adjuvant treatment; SurgerySettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIADisease ManagementPHASE-III TRIALRANDOMIZED CONTROLLED-TRIALNeoadjuvant TherapyQuality assuranceColon cancerEuropemedicine.anatomical_structureTreatment OutcomeOncologyTRANSANAL ENDOSCOPIC MICROSURGERYColonic NeoplasmsPractice Guidelines as TopicHYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPYmedicine.medical_specialtyNeoadjuvant treatmentEvidence-based practiceConsensusLYMPH-NODE EVALUATIONDelphi methodRectumAuditSDG 3 - Good Health and Well-beingHumansCIRCUMFERENTIAL RESECTION MARGINddc:610business.industryRectal NeoplasmsTOTAL MESORECTAL EXCISIONCancerLONG-TERM SURVIVALAuditAdjuvant treatmentmedicine.diseaseSurgeryOncology nursingFamily medicineSurgeryMultidisciplinary teamsbusiness
researchProduct

On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion

2021

Radiochemical conversion is an important term to be included in the "Consensus nomenclature rules for radiopharmaceutical chemistry". Radiochemical conversion should be used to define reaction efficiency by measuring the transformation of components in a crude reaction mixture at a given time, whereas radiochemical yield is better suited to define the efficiency of an entire reaction process including, for example, separation, isolation, filtration, and formulation. (C) 2020 Elsevier Inc. All rights reserved.

Cancer ResearchRadiochemistryNomenclatureRadiochemical conversionChemistryRadiochemistry610 Medicine & health10181 Clinic for Nuclear MedicineTerminology030218 nuclear medicine & medical imagingNuclear chemistryRadiochemical yield03 medical and health sciences0302 clinical medicineddc:5701313 Molecular Medicine030220 oncology & carcinogenesisYield (chemistry)2741 Radiology Nuclear Medicine and ImagingMolecular Medicine1306 Cancer ResearchRadiology Nuclear Medicine and imagingRadiopharmaceutical sciencesConsensus guidelinesNuclear Medicine and Biology
researchProduct

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

2007

Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are pr…

Cancer Researchmedicine.medical_specialtyMEDLINElymphomaComorbiditySettore MED/08 - Anatomia PatologicaAntiviral AgentsImmunophenotypingDiagnosis DifferentialAntibodies Monoclonal Murine-DerivedBone MarrowAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansCombined Modality TherapySplenic marginal zone lymphomaIntensive care medicineSplenic marginal zone lymphomaNeoplasm StagingChromosome Aberrationsbusiness.industrySplenic NeoplasmsAntibodies MonoclonalDisease ManagementLymphoma B-Cell Marginal ZoneHematologyHepatitis C ChronicPrognosismedicine.diseaseCombined Modality TherapyComorbidityLymphomaSurgeryClinical trialOncologyPractice Guidelines as TopicSplenectomyRituximabDifferential diagnosisRituximabbusinessguidelineSpleenmedicine.drugLeukemia
researchProduct

European code against cancer 4th edition: 12 ways to reduce your cancer risk

2015

AbstractThis overview describes the principles of the 4th edition of the European Code against Cancer and provides an introduction to the 12 recommendations to reduce cancer risk. Among the 504.6 million inhabitants of the member states of the European Union (EU28), there are annually 2.64 million new cancer cases and 1.28 million deaths from cancer. It is estimated that this cancer burden could be reduced by up to one half if scientific knowledge on causes of cancer could be translated into successful prevention. The Code is a preventive tool aimed to reduce the cancer burden by informing people how to avoid or reduce carcinogenic exposures, adopt behaviours to reduce the cancer risk, or t…

Cancer Researchmedicine.medical_specialtyQuality Assurance Health CareEpidemiologyUterine Cervical NeoplasmsCancer preventionCauses of cancerCancer screeningBreast cancerRisk FactorsEnvironmental healthCancer screeningmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unionPreventive healthcaremedia_commonCervical cancerCancer risk factorsCancer preventionbusiness.industryCancermedicine.diseaseEuropeOncology1117 Public Health And Health ServicesWorking Groups of Scientific ExpertsPractice Guidelines as TopicFemalebusiness1112 Oncology And Carcinogenesis
researchProduct

The Italian validation of the Montreal Global definition and classification of gastroesophageal reflux disease

2009

Recently, a Global definition and a classification of gastroesophageal reflux disease (GERD) were developed by Montreal Consensus Group, composed of international expert gastroenterologists. Guidelines and consensus documents are, however, infrequently accepted and adopted at a local level. The aim of this study was to measure the acceptance of Montreal Global definition of GERD consensus document by specialists in a single country (Italy) and to measure the linguistic, scientific, and practical differences between the international consensus document and the Italian version.A 2-day meeting was held in June 2007 in Rome, Italy, attended by 147 Italian physicians who were experts in gastroen…

Chest Painmedicine.medical_specialtyValidation studyEsophageal NeoplasmseducationMEDLINEDiseaseAdenocarcinomaGastroenterologyBarrett EsophagusTerminology as TopicInternal medicineHumansMedicineLanguageEvidence-Based MedicineHepatologybusiness.industryGastroenterologyRefluxSyndromeEvidence-based medicinemedicine.diseasedigestive system diseasesItalyEsophageal stenosisFamily medicinePractice Guidelines as TopicEsophageal StenosisGastroesophageal RefluxGERDbusinessPremalignant lesionEuropean Journal of Gastroenterology & Hepatology
researchProduct

Diagnostic algorithm for familial chylomicronemia syndrome

2016

International audience; Background: Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia often associated with recurrent episodes of pancreatitis. The recognition and correct diagnosis of the disease is challenging due to its rarity, and to the lack of specificity of signs and symptoms. Lipid experts, endocrinologists, gastroenterologists, pancreatologists, and general practitioners may encounter patients who potentially have FCS. Therefore, cooperation between experts and improved knowledge of FCS is essential in improving the diagnosis. Currently, a consensus on best practice for the diagnosis of FCS is lacking. Methods: Aiming to def…

Chylomicrons; Familial chylomicronemia syndrome; Hyperlipoproteinemia; Lipoprotein lipase deficiency; Pancreatitis; Biomarkers; Genetic Markers; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type I; Lipids; Lipoprotein Lipase; Phenotype; Practice Guidelines as Topic; Predictive Value of Tests; Prognosis; Algorithms; Critical Pathways; DNA Mutational Analysis; Decision Support Techniques; Mutation; Internal Medicine; Cardiology and Cardiovascular MedicineSettore MED/09 - Medicina InternaACUTE-PANCREATITIS[SDV]Life Sciences [q-bio]DNA Mutational AnalysisPredictive Value of TestDisease030204 cardiovascular system & hematologyVARIANTSDecision Support Technique0302 clinical medicineDOMAINGenetic MarkerBINDINGChylomicronsHYPERTRIGLYCERIDEMICMedicine030212 general & internal medicinePANCREATITISLipoprotein lipase deficiencyGeneral MedicineFamilial ChylomicronemiaLipidPrognosisLipids3. Good healthAlgorithmDEFICIENCYPhenotypeCritical PathwayPractice Guidelines as TopicCritical PathwaysHyperlipoproteinemia Type Ilipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAlgorithmAlgorithmsHumanGenetic MarkersSevere hypertriglyceridemiaFamilial chylomicronemia syndromePrognosiSigns and symptomsLIPOPROTEIN-LIPASEHyperlipoproteinemiaCLASSIFICATIONDecision Support TechniquesSecondary careChylomicronDNA Mutational Analysi03 medical and health sciencesPredictive Value of TestsInternal MedicineMANAGEMENTHumansGenetic Predisposition to DiseasePancreatitibusiness.industryBiomarkerLipoprotein LipaseMutationbusinessBiomarkers
researchProduct

Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA(2)LEN taskforce position paper

2010

The GA(2)LEN taskforce on Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) published in 2009 a position paper concerning PROS and HRQoL assessment in clinical trials on allergy. Because of the specificity of this topic in asthma and rhinitis, specific recommendations are needed. The aim of this position paper is to define PROs and their meaning in asthma and rhinitis research, explore the available tools to provide criteria for a proper choice, identify patient-related factor which could influence PROs assessment, define specific recommendations for assessment, analysis and results spreading, underline the unexplored areas and unmet needs. PROs assessment is gaini…

Clinical Trials as TopicRhinitis Allergic PerennialHealth Planning GuidelinesRhinitis Allergic SeasonalAsthmahumanitiesOutcome Assessment (Health Care)Treatment OutcomeResearch DesignRhinitis Allergic Perennial; Humans; Rhinitis Allergic Seasonal; Health Planning Guidelines; Treatment Outcome; Clinical Trials as Topic; Quality of Life; Asthma; Outcome Assessment (Health Care); Research DesignHealth Planning GuidelineOutcome Assessment Health CareQuality of LifeHumansRinite Alérgica SazonalAsmaRhinitiQualidade de VidaHuman
researchProduct

Collecting large cohorts of patients with uncommon diseases: mission impossible?

2007

Cohort StudiesAnalysis of VariancePubMedBiomedical ResearchRare DiseasesElectronic MailMultivariate AnalysisPractice Guidelines as TopicHumansSicilyuncommon diseases
researchProduct